Black Rock Inc. Dbv Technologies S.A. Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.3 - $1.88 $133,027 - $192,378	-102,329 Reduced 10.06%	915,341 $1.24 Million
Q2 2023 Aug 11, 2023	BUY	$1.42 - $2.23 $63,067 - $99,043	44,414 Added 4.56%	1,017,670 $1.93 Million
Q1 2023 May 12, 2023	SELL	$1.28 - $1.73 $104,217 - $140,856	-81,420 Reduced 7.72%	973,256 $1.64 Million
Q4 2022 Feb 13, 2023	BUY	$1.16 - $1.8 $14,088 - $21,861	12,145 Added 1.16%	1,054,676 $1.61 Million
Q3 2022 Nov 14, 2022	SELL	$1.77 - $2.76 $45,897 - $71,569	-25,931 Reduced 2.43%	1,042,531 $1.85 Million

Q2 2022 Aug 12, 2022	BUY	$1.15 - $3.25 $438,289 - $1.24 Million	381,121 Added 55.45%	1,068,462 $2.72 Million
Q1 2022 May 12, 2022	BUY	$1.22 - $1.77 $118,842 - $172,419	97,412 Added 16.51%	687,341 $1.09 Million
Q4 2021 Feb 10, 2022	BUY	$1.39 - $5.58 $788,934 - $3.17 Million	567,579 Added 2539.5%	589,929 $944,000
Q3 2021 Nov 09, 2021	BUY	$4.71 - $5.92 $39,667 - $49,858	8,422 Added 60.47%	22,350 $110,000
Q2 2021 Aug 11, 2021	BUY	$5.32 - $6.53 $74,096 - $90,949	13,928 New	13,928 $76,000

37.7M

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $175M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.